MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 326766 | Name: Faropenem medoxomil
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Faropenem medoxomil, also known as Faropenem daloxate or Faropenem medoxil, is an orally active beta-lactam antibiotic belonging to the penem group. It is resistant to some forms of extended-spectrum beta-lactamase. Faropenem medoxomil is a prodrug of Faropenem.

Chemical Structure

Faropenem medoxomil
Faropenem medoxomil
CAS#141702-36-5

Theoretical Analysis

MedKoo Cat#: 326766

Name: Faropenem medoxomil

CAS#: 141702-36-5

Chemical Formula: C17H19NO8S

Exact Mass: 397.0831

Molecular Weight: 397.40

Elemental Analysis: C, 51.38; H, 4.82; N, 3.52; O, 32.21; S, 8.07

Price and Availability

Size Price Availability Quantity
50mg USD 750.00 2 Weeks
100mg USD 1,250.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
141702-36-5 16559-89-1
Synonym
Faropenem medoxomil; Faropenem daloxate; Fropenem daloxate; Faropenem medoxil; BAY-56-6854; BAY 56-6854; BAY56-6854; BAY-566854; BAY 566854; BAY566854; SUN-208; SUN208; SUN 208
IUPAC/Chemical Name
(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl (5R,6S)-6-((R)-1-hydroxyethyl)-7-oxo-3-((R)-tetrahydrofuran-2-yl)-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate
InChi Key
JQBKWZPHJOEQAO-DVPVEWDBSA-N
InChi Code
InChI=1S/C17H19NO8S/c1-7(19)11-14(20)18-12(13(27-15(11)18)9-4-3-5-23-9)16(21)24-6-10-8(2)25-17(22)26-10/h7,9,11,15,19H,3-6H2,1-2H3/t7-,9-,11+,15-/m1/s1
SMILES Code
O=C(C(N12)=C([C@@H]3OCCC3)S[C@]2([H])[C@@H]([C@H](O)C)C1=O)OCC4=C(C)OC(O4)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 397.40 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Nayak S, Pai U, Birla A. Role of Faropenem in Treatment of Pediatric Infections: The Current State of Knowledge. Cureus. 2022 Apr 25;14(4):e24453. doi: 10.7759/cureus.24453. PMID: 35497081; PMCID: PMC9045788. 2: Gettig JP, Crank CW, Philbrick AH. Faropenem medoxomil. Ann Pharmacother. 2008 Jan;42(1):80-90. doi: 10.1345/aph.1G232. Epub 2007 Dec 19. PMID: 18094341. 3: Bhanja DB, Sil A, Panigrahi A, Chakraborty S, Datta M. Faropenem-induced urticarial vasculitis. Indian J Dermatol Venereol Leprol. 2021 Jan- Feb;87(1):146. doi: 10.25259/IJDVL_1052_19. PMID: 33580928. 4: Gandra S, Takahashi S, Mitrani-Gold FS, Mulgirigama A, Ferrinho DA. A systematic scoping review of faropenem and other oral penems: treatment of Enterobacterales infections, development of resistance and cross-resistance to carbapenems. JAC Antimicrob Resist. 2022 Dec 22;4(6):dlac125. doi: 10.1093/jacamr/dlac125. PMID: 36570688; PMCID: PMC9777757. 5: Hadley JA, Tillotson GS, Tosiello R, Echols RM. Faropenem medoxomil: a treatment option in acute bacterial rhinosinusitis. Expert Rev Anti Infect Ther. 2006 Dec;4(6):923-37. doi: 10.1586/14787210.4.6.923. PMID: 17181408. 6: Schurek KN, Wiebe R, Karlowsky JA, Rubinstein E, Hoban DJ, Zhanel GG. Faropenem: review of a new oral penem. Expert Rev Anti Infect Ther. 2007 Apr;5(2):185-98. doi: 10.1586/14787210.5.2.185. PMID: 17402834. 7: Gandra S, Choi J, McElvania E, Green SJ, Harazin M, Thomson RB, Dantas G, Singh KS, Das S. Faropenem resistance causes in vitro cross-resistance to carbapenems in ESBL-producing Escherichia coli. Int J Antimicrob Agents. 2020 Mar;55(3):105902. doi: 10.1016/j.ijantimicag.2020.105902. Epub 2020 Jan 17. PMID: 31954833. 8: Lucic A, Hinchliffe P, Malla TR, Tooke CL, Brem J, Calvopiña K, Lohans CT, Rabe P, McDonough MA, Armistead T, Orville AM, Spencer J, Schofield CJ. Faropenem reacts with serine and metallo-β-lactamases to give multiple products. Eur J Med Chem. 2021 Apr 5;215:113257. doi: 10.1016/j.ejmech.2021.113257. Epub 2021 Feb 9. PMID: 33618159; PMCID: PMC7614720. 9: Faropenem medoxomil: A0026, BAY 56-6854, BAY 566854, faropenem daloxate, SUN 208, SUN A0026. Drugs R D. 2008;9(2):115-24. doi: 10.2165/00126839-200809020-00005. PMID: 18298129. 10: Day KM, Pike R, Winstanley TG, Lanyon C, Cummings SP, Raza MW, Woodford N, Perry JD. Use of faropenem as an indicator of carbapenemase activity in the Enterobacteriaceae. J Clin Microbiol. 2013 Jun;51(6):1881-6. doi: 10.1128/JCM.00720-13. Epub 2013 Apr 10. PMID: 23576544; PMCID: PMC3716051. 11: Dharmapalan D, Chandy SJ. Oral Faropenem Sodium - Implications for Antimicrobial Resistance and Treatment Effectiveness. Indian Pediatr. 2022 Nov 15;59(11):879-881. PMID: 36370017. 12: Gandra S, Klein EY, Pant S, Malhotra-Kumar S, Laxminarayan R. Faropenem Consumption is Increasing in India. Clin Infect Dis. 2016 Apr 15;62(8):1050-2. doi: 10.1093/cid/ciw055. Epub 2016 Feb 7. Erratum in: Clin Infect Dis. 2017 Aug 1;65(3):533. PMID: 26908807. 13: Srivastava S, Cirrincione KN, Deshpande D, Gumbo T. Tedizolid, Faropenem, and Moxifloxacin Combination With Potential Activity Against Nonreplicating Mycobacterium tuberculosis. Front Pharmacol. 2021 Jan 19;11:616294. doi: 10.3389/fphar.2020.616294. PMID: 33542690; PMCID: PMC7851080. 14: Gurumurthy M, Verma R, Naftalin CM, Hee KH, Lu Q, Tan KH, Issac S, Lin W, Tan A, Seng KY, Lee LS, Paton NI. Activity of faropenem with and without rifampicin against Mycobacterium tuberculosis: evaluation in a whole-blood bactericidal activity trial. J Antimicrob Chemother. 2017 Jul 1;72(7):2012-2019. doi: 10.1093/jac/dkx081. PMID: 28333342. 15: Xing X, Ma P, Huang Q, Qi X, Zou B, Wei J, Tao L, Li L, Zhou G, Song Q. Predicting Pharmacokinetics Variation of Faropenem Using a Pharmacometabonomic Approach. J Proteome Res. 2020 Jan 3;19(1):119-128. doi: 10.1021/acs.jproteome.9b00436. Epub 2019 Dec 2. PMID: 31617722. 16: Hamilton-Miller JM. Chemical and microbiologic aspects of penems, a distinct class of beta-lactams: focus on faropenem. Pharmacotherapy. 2003 Nov;23(11):1497-507. doi: 10.1592/phco.23.14.1497.31937. PMID: 14620395. 17: Deshpande D, Srivastava S, Nuermberger E, Pasipanodya JG, Swaminathan S, Gumbo T. A Faropenem, Linezolid, and Moxifloxacin Regimen for Both Drug- Susceptible and Multidrug-Resistant Tuberculosis in Children: FLAME Path on the Milky Way. Clin Infect Dis. 2016 Nov 1;63(suppl 3):S95-S101. doi: 10.1093/cid/ciw474. PMID: 27742640; PMCID: PMC5064155. 18: Jones RN, Critchley IA, Whittington WL, Janjic N, Pottumarthy S. Activity of faropenem tested against Neisseria gonorrhoeae isolates including fluoroquinolone-resistant strains. Diagn Microbiol Infect Dis. 2005 Dec;53(4):311-7. doi: 10.1016/j.diagmicrobio.2005.06.014. Epub 2005 Nov 2. PMID: 16269221. 19: Dalhoff A, Nasu T, Okamoto K. Target affinities of faropenem to and its impact on the morphology of gram-positive and gram-negative bacteria. Chemotherapy. 2003 Jul;49(4):172-83. doi: 10.1159/000071141. PMID: 12886052. 20: Hu F, Ahn C, O'Hara JA, Doi Y. Faropenem disks for screening of Klebsiella pneumoniae carbapenemase-producing Enterobacteriaceae. J Clin Microbiol. 2014 Sep;52(9):3501-2. doi: 10.1128/JCM.02837-13. PMID: 25143417; PMCID: PMC4313199.